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SUMMARY
We show here that inducible expression of BrafV600E off the endogenous Braf gene in mouse melanocytes
stimulates skin hyperpigmentation and the appearance of nevi harboring senescent melanocytes. Addition-
ally, approximately 70% of BrafV600E mice develop melanomas that reproduce many of the cardinal histolog-
ical and molecular features of human melanoma and whose cells can colonize the lungs of nude mice. We
show that the tumor suppressor p16INK4a is not required to induce melanocyte senescence and that its
loss is not required for tumor progression, although it does regulate tumor penetrance and latency. Thus,
we have developed a mouse model of melanoma driven by BrafV600E expressed at physiological levels
that reflects the genetics and pathology of the human disease.INTRODUCTION
Melanoma is an aggressive form of skin cancer that arises from
cells called melanocytes, specialized pigmented cells that
provide skin tone, hair color, and protection from ultraviolet
radiation. The serine/threonine-specific protein kinase BRAF,
a component of the RAS/RAF/MEK/ERK signaling pathway, is
a key player in melanoma because it is activated by somatic
gain-of-function mutations in 50%–70% of human melanomas,
making it the most frequently mutated oncogene in this disease
(Garnett and Marais, 2004). A substitution of glutamic acid for
valine at position 600 (V600E) is the most common mutation in
BRAF in melanoma (occurring in over 90% of cases), and
BRAFV600E stimulates constitutive cell signaling, growth factor-
independent proliferation, and transformation of immortalized
melanocytes, allowing these cells to grow as tumors in nude
mice (Hingorani et al., 2003; Hoeflich et al., 2006; Karasarides
et al., 2004; Wellbrock et al., 2004). Inhibitors of BRAFV600E
signaling blockmelanoma cell proliferation and induce apoptosisin vitro; in vivo they slow the growth of melanoma xenografts.
These data demonstrate that BRAFV600E is necessary for the
maintenance and progression of melanoma in humans.
Despite its clear association with tumor maintenance and
progression, overexpression of BRAFV600E in zebrafish melano-
cytes only induces nevus-like clusters of cells that do not
progress to melanoma unless p53 is also deleted (Patton et al.,
2005). Furthermore, BRAFV600E mutations are found in up to
80% of human nevi, benign melanocytic lesions that can remain
unchanged for decades (Pollock et al., 2003), and BRAFV600E
induces classical oncogene-induced senescence in human
melanocytes in vitro (Gray-Schopfer et al., 2006; Michaloglou
et al., 2005). Together, these data indicate that BRAFV600E is
not sufficient for melanoma induction and that additional genetic
or epigenetic changes are required to induce full melanocyte
transformation. Furthermore, the data do not reveal whether
BRAFV600E is a founder, a driver, or a passenger mutation in
melanomagenesis, a question that cannot be addressed using
approaches that rely on transformation of immortalizedSIGNIFICANCE
BRAF is mutated in 50%–70% of humanmelanomas, and we have developed a mouse model of melanoma that is driven by
BrafV600E, the most common BRAFmutant found in the human disease. This model is important because it is driven by the
most relevant human oncogene expressed at physiological levels. The close similarities between the tumors that develop in
our mice and those seen in humans show that we can now dissect melanoma genetics and study its pathology in this highly
tractable model system. Notably, our data establish that BrafV600E can induce melanocyte senescence in vivo and that the
acquisition of a BRAF mutation can be a founder event in melanomagenesis.
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patients with existing metastatic disease.
The purpose of this work was to develop a mouse model of
melanoma driven by oncogenic Braf that would emulate the
human disease. Specifically, we wished to mimic the acquisition
of somatic BRAF mutations that occurs in human melanoma by
expressing BrafV600E in the melanocytes of postnatal mice using
the endogenous Braf gene. Our aim was to determine whether
expression of BrafV600E at physiological levels could induce
melanoma in mice, to use these mice to investigate the role of
p16INK4a in melanoma progression, and to determine whether
the acquisition of a Braf mutation could be a founder mutation
in melanoma.
RESULTS
To develop ourmousemodel ofmelanoma,we used a transgenic
mouse strain (LSL-BrafV600E) that we previously developed that
allows inducible expression of BrafV600E off the endogenous
Braf gene using LoxP-stop-LoxP (LSL)/Cre recombinase tech-
nology (see Figure S1 available online; Mercer et al., 2005).
Table 1. Genotyping of Pups Resulting from Intercross between
Braf+/LSL-V600E and Tyr::CreERT2+/o Mice
Genotype Phenotype Expected Observed
Braf+/+;Tyr::CreERT2o/o wild-type 25% 27% (102)
Braf+/LSL-V600E;
Tyr::CreERT2o/o
BrafV600E 25% 25% (93)
Braf+/+;Tyr::CreERT2+/o CreERT2 25% 22% (82)
Braf+/LSL-V600E;
Tyr::CreERT2+/o
BrafV600E/CreERT2 25% 26% (99)
The expected and observed frequency of each genotype is shown as
a percentage, with the absolute numbers of individuals shown in paren-
theses.BrafV600E expression from this locus is normally suppressed by
the presence of a minigene encoding wild-type Braf and the
NeoR cassette used for embryonic stem cell selection. However,
expression can be induced when the locus is rearranged
by Cre recombinase. To regulate the rearrangement of the
LSL-BrafV600E locus, a tamoxifen (TM)-activated version of Cre
recombinase (CreERT2; Indra et al., 1999) was placed under
the control of a tyrosinase enhancer/promoter construct (Yajima
et al., 2006), allowing precise control of BrafV600E expression in
melanocytes in postnatal mice. Since BrafV600E is expressed
off the endogenous gene and expression can be regulated by
TM treatment, this approach closely mimics the somatic acqui-
sition of BRAF mutations that occurs in human melanoma.
LSL-BrafV600E mice were crossed to Tyr::CreERT2+/o mice, and
double-targeted LSL-BrafV600E;Tyr::CreERT2+/o (hereafter
referred to as BrafV600E/CreERT2) mice were obtained at the ex-
pected Mendelian ratio (Table 1). The untreated double-targeted
mice appeared normal, were fertile, and exhibited a normal life
span (data not shown).
To induce BrafV600E expression, TMwas applied to the shaven
skin on backs of the mice 2–3 months after birth. Two TM treat-
ment schedules (8 treatments over 8 days versus 4 treatments
over 7 days) at two doses (20 mg versus 1 mg) were tested,
and within 2 months, the BrafV600E/CreERT2 mice developed
skin hyperpigmentation independently of the treatment
schedule used. Their snouts, tails, ears, and paws all darkened
visibly (Figures 1A–1D). This systemic effect was unexpected
because TM was only applied to a small section of skin on the
backs of the mice (approximately 1 cm2) and suggests that
TM was absorbed into the circulation through the dermis or
was ingested during grooming after treatment. Skin hyperpig-
mentation due to increased melanocyte proliferation is also
seen when HrasG12V or NrasQ61K is overexpressed using mela-
nocyte-specific promoters (Ackermann et al., 2005; Powell
et al., 1995), but we also observed less penetrant phenotypes,Figure 1. Phenotype of BrafV600E-Expressing Mice
The comparison shown here is between tamoxifen (TM)-treated BrafWT (Braf+/+;Tyr::CreERT2+/o) and BrafV600E (LSL-BrafV600E;Tyr::CreERT2+/o) mice.
(A) BrafWT and BrafV600E siblings.
(B) Tails of BrafWT and BrafV600E mice.
(C) Ears of BrafWT and BrafV600E mice.
(D) Feet of BrafWT and BrafV600E mice.
(E) Proximal toenail of the right hind foot of a BrafV600E mouse (arrow).
(F) Anterior nipple of a BrafV600E female mouse (arrow).
(G) Skin from the inside of BrafWT and BrafV600E mice.Cancer Cell 15, 294–303, April 7, 2009 ª2009 Elsevier Inc. 295
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(A) Photograph of the back of a BrafV600E mouse after treat-
ment with four 20 mg doses of TM. The fur has been removed
to reveal the nevi.
(B) Photograph of the back of a BrafV600E mouse after treat-
ment with four 1 mg doses of TM. The fur has been removed
to reveal the nevi.
(C) Enlargement of the region indicated in (B).
(D–G) Photomicrographs of nevi from the backs of TM-treated
BrafV600E mice. The indicated region in (E) is magnified in (F)
and shows the presence of epithelioid (arrow) and spindle
dendritic (arrowheads) cells. (G) shows a symmetrical lesion
with pushing borders displaying an area of unpigmented
differentiated cells resembling a hypopigmented blue nevus
(Carr et al., 1997). Scale bars = 500 mm in (D), (E), and (G);
100 mm in (F).
(H) Photographs of the TM-treated area of a BrafV600E mouse
taken 14 and 19 months after TM treatment.
(I and J) Sections of a nevus stained for hematoxylin and eosin
and senescence-associated (SA)-b-galactosidase (light blue).
The indicated region in (I) is magnified in (J). Note the
expression of SA-b-galactosidase in melanocytic cells. Scale
bars = 500 mm in (I); 100 mm in (J).
(K and L) Deeper aspect of a nevus where melanocytic cells
are encasing a nerve bundle. The neoplastic cells express
SA-b-galactosidase (light blue) and fail to display Ki-67
nuclear staining (DAB/brown; similar results were observed
with other chromogens, including AEC). Note the presence
of a cluster of melanophages in the bottom right corner. Scale
bars = 100 mm.including darkening of the toenails proximal to the body on the
front and/or hind feet (equivalent to human thumbs or big toes;
Figure 1E) in 40% of the animals and darkening of anterior
nipples (Figure 1F) in 50% of the females. The hairy skin also
darkened, visible most clearly when examined from the inside
and generally only within the TM-treated areas (Figure 1G). No
such phenotypes were observed in ethanol-treated BrafV600E/
CreERT2 mice or in TM-treated controls that included
LSL-BrafV600E- and Tyr::CreERT2-only targeted mice (Figure 1
and data not shown).
BrafV600E expression also induced nevi in all of the animals
(Figures 2A–2C). These were most abundant in the TM-treated
areas but occasionally appeared in untreated areas such as
the ears and belly (data not shown). They were more widespread
on mice treated with high doses of TM (compare Figure 2A and
Figure 2B) and were not seen in ethanol-treated BrafV600E/
CreERT2 controls or other TM-treated mice. The nevi appeared
as pigmented dome-shaped outgrowths in the dermis (Fig-
ure 2C). They were never located in the epidermis and did not
possess a junctional (epidermal/dermal crossover) component
(Figures 2D and 2E). These lesions were composed of
pigmented epithelioid or dendritic melanocytes (arrow and
arrowheads, respectively, in Figure 2F). Neuroid differentiation,
producing regions of unpigmented cells, occurred below the
nevus in some cases, and a clearly defined border was still
evident (Figure 2G). The histopathological features of theselesions were consistent with those of human blue nevi. These
nevi did not undergo obvious changes in morphology or pigmen-
tation over extended periods of the life span of the mice
(Figure 2H), and they stained positive for senescence-associ-
ated (SA)-b-galactosidase, particularly in their deeper aspects
(Figures 2I–2L). The absence of mitotic figures (data not shown)
and lack of staining for the proliferation marker Ki-67 (Figure 2L)
demonstrated that these lesions possessed low levels of cell
proliferation.
BrafV600E also induced large melanocytic lesions around the
perianal regions and in the eyelids of the mice (Figures 3A and
3B). Multiple blue nevi as described above were often adjacent
to, but not contiguous with, these lesions. Those in the eyelids
arose 3–5 months after BrafV600E expression and occurred in
80% of animals, whereas the perianal lesions appeared after
6–10 months and generally only in the animals treated with
high doses of TM. These lesions (anal lesions, Figures 3C–3E;
eyelid lesions, Figures 3F and 3G) were dome-shaped and
composed of a complexmixture of heavily pigmented epithelioid
cells (Figure 3D, white arrowheads), which dominated the central
aspects, and spindle melanocytic cells (Figure 3D, black arrow-
heads), which predominated at the periphery. The large, epithe-
lioid-shaped melanocytes were admixed with less densely
pigmented epithelioid melanocytes and melanophages. The
neoplastic cells contained uniform, round nuclei, with vesicular
chromatin and small but discrete nucleoli (Figure 3H). In the
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(A) Photograph showing large pigmented perianal
lesion in a BrafV600E-expressing mouse treated
with four 20 mg doses of TM (right), compared to
a BrafWT control mouse (left).
(B) Photograph showingmelanocytic lesions in the
eyelids of a BrafV600E expressing mouse treated
with four 20 mg doses of TM (right), compared to
a similarly treated BrafWT mouse (left).
(C) Photomicrograph of a section from a large pig-
mented perianal epithelioid blue nevus stained
with hematoxylin and eosin. Scale bar = 500 mm.
(D) Photomicrograph of a magnified region of an
epithelioid blue nevus displaying large heavily
and lightly pigmented epithelioid melanocytic cells
(white arrowheads) and a small number of lightly
pigmented spindle-shaped melanocytes (black
arrowheads), occasionally with dendritic projec-
tions. Scale bar = 100 mm.
(E) Photomicrograph of an epithelioid blue nevus
showing dendritic cells extending along the peri-
adnexal structures of the skin. Scale bar = 100 mm.
(F and G) Low-power magnification of epithelioid
blue nevi of the eyelid. Note the presence of
epidermal hyperplasia and that the lesion is
composed of epithelioid cells with varying degrees
of pigmentation and spindle cells. Scale bars =
500 mm in (F); 100 mm in (G).
(H) High-powermagnification of an epithelioid blue
nevus composed of spindle (arrowheads) and
epithelioid cells. Note the presence of a mitotic
figure (arrow). Scale bar = 100 mm.epithelioid cells, the cytoplasm was abundant and heavily
melanin laden (Figures 3C, 3D, 3F, and 3G). Heavily pigmented
cells could be found throughout the lesions, including at the
base (Figures 3C, 3F, and 3G). A small number of lightly pig-
mented spindle-shaped melanocytes with poorly defined cell
borders were also observed (Figures 3D and 3H; black arrow-
heads). Many of these cells were arranged either haphazardly
or in short fascicles. The spindle cells often displayed dendritic
extensions (Figures 3E and 3H) and spread to the subcutaneous
adipose tissue along the periadnexal connective tissue of the
hair follicles, pilar muscle, eccrine coils, or neovascular bundles
(Figures 3C and 3E–3G). As with the ordinary blue nevi, these
lesions were largely restricted to the dermal layers of the skin,
and epidermal hyperplasia was observed (Figures 3C, 3F, and
3G). Rare mitotic figures (one mitosis in 30 high-power fields;
Figure 3H, arrow) were seen, but never at the base of the lesions.
These histological features are consistent with a diagnosis of
epithelioid blue nevus, originally described in patients with
Carney complex but also found as sporadic solitary lesions
(Moreno et al., 2000; Zembowicz et al., 2004). It has been sug-
gested that epithelioid blue nevi are variants of blue nevi (Groben
et al., 2000), and the coexistence of both blue nevi and epithe-
lioid blue nevi in our mice is consistent with this hypothesis.
Furthermore, as in the mice described here, epithelioid blue
nevi have also been observed to arise in genital mucosal areas
in humans (Izquierdo et al., 2001).
BrafV600E also induced rapidly growing hypopigmented
tumors in 60%–70% of the mice (Figure 4A). These were asym-
metrical and displayed an overt locally destructive growthpattern (Figure 4B; Figures S2A and S2B). Remnants of blue
nevi that were contiguous with the tumors were seen occasion-
ally (Figure 4C, arrowheads), and no junctional components were
found. These poorly circumscribed lesions were centered at the
superficial dermis, often (38%) ulcerated the overlying epidermis
(Figures 4B and 4C; Figures S2C and S2D), and infiltrated the
subcutis, skeletal muscle, and auricular cartilage in a destructive
fashion (Figures 4B, 4J, and 4K; Figures S2A and S2B). The
tumors were composed of a mixture of (1) atypical spindle and
plump spindle cells either arranged in short fascicles
(Figure 4D; Figures S2E and S2F) occasionally in storiform
pattern or immersed in amyxoidmatrix and (2) discohesive atyp-
ical epithelioid cells (Figures 4E–4G; Figures S2G and S2H), with
pleomorphic nuclei containing conspicuous nucleoli (Figure 4E–
4G), that were either isolated or vaguely arranged into nests
(Figure 4E–4I). Although no lymphocytic infiltrate or pagetoid
cells were found, these lesions displayed several histological
and cytological features of cells usually found in malignant
melanomas: increased nuclear/cytoplasmic ratios (Figures 4F
and 4G) together with atypical and pleomorphic nuclei (Figures
4E–4G and 4J) and numerous nuclear pseudoinclusions (Figures
4D, 4F, 4H, and 4I, arrows). Rare, morphologically unequivocal
neoplastic cells containing dusty brownish cytoplasmic pigment
(Figures 4D and 4G) that were positive for Masson-Fontana stain
(data not shown) were observed, and abundant mast cells were
also present throughout the lesions. Areas of necrosis within the
tumor bulk were often observed (Figure S2D). Clusters of mela-
nophages, mostly restricted to the superficial aspects of the
lesions, were also often found (data not shown). Additionally,–303, April 7, 2009 ª2009 Elsevier Inc. 297
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(A) Photograph showing a large hypopigmented tumor on a TM-treated
BrafV600E mouse. The fur has been removed to reveal the lesion.
(B) Scanning magnification of an oligomelanotic malignant melanoma
demonstrating its asymmetry, destructive growth pattern, and ulceration.
Scale bar = 0.5 cm.
(C) High-power magnification of the region indicated in (B) of a BrafV600E-
induced tumor showing remnants of a nevus at its periphery (arrowheads)
and ulceration. Scale bar = 200 mm.
(D) Deep area composed predominantly of spindle cells, some of which harbor
nuclear pseudoinclusions (arrow). Note the presence of numerous pigmented
spindle cells with long dendritic cytoplasmic projections (arrowheads). Scale
bar = 50 mm.
(E) Discohesive epithelioid neoplastic cells are occasionally arranged in
a vaguely nested pattern (arrowheads). Scale bar = 200 mm.
(F and G) Atypical epithelioid neoplastic cells displaying increased nuclear
cytoplasmic ratios and pleomorphic nuclei with conspicuous nucleoli. Rare
rhabdoid cells could also be found. Note the presence of nuclear pseudoinclu-
sions (arrow in [F]) and cells with dusty, intracytoplasmic brown pigment
(arrowhead in [G]). A mitotic figure is also indicated in (F) (arrowhead). Scale
bars = 50 mm.
(H) Neoplastic cells displaying numerous nuclear pseudoinclusions (arrows).
Scale bar = 50 mm.
(I) Neoplastic cells arranged in a vaguely nested pattern displaying numerous
nuclear pseudoinclusions (arrows). Note the presence of a mitotic figure
(arrowhead). Scale bar = 50 mm.
(J) Deep area of an oligomelanotic melanoma composed of spindle cells
infiltrating the skeletal muscle. Note the presence of numerous mitotic figures
(arrowheads). Scale bar = 50 mm.
(K) Left: deep area of a predominantly spindle cell malignant melanoma
infiltrating the skeletal muscle. Right: serial section subjected to immunohisto-
chemical analysis with antibodies against Ki-67 (MIB1) highlighting the298 Cancer Cell 15, 294–303, April 7, 2009 ª2009 Elsevier Inc.these lesions typically showed significantly increased levels of
mitotic activity compared to nevi. Mitotic figures, which were
extremely rare in the nevi (Figure 3H), were common in the
tumors (Figures 4F, 4I, and 4J, arrowheads), with an average
mitotic index of 11 mitoses/10 high-power fields (10 tumors
analyzed). Mitotic figures were observed in both the superficial
and deep aspects of the lesions (Figure 4J), and atypical mitotic
figures were readily observed. Ki-67 labeling indices ranged
from 11% to 28%, and Ki-67-positive nuclei were present
throughout the lesions, including within their deep aspects
(Figure 4K).
Positive immunoreactivity for S100, a common marker for
melanoma (Ohsie et al., 2008), was observed in all tumors
(Figures 5A and 5B). Interestingly, even the lesions composed
predominantly of spindle cells arranged in storiform pattern
were diffusely positive for S100, suggesting that these tumors
were not malignant peripheral nerve sheath tumors (King et al.,
1999). In addition to S100, antibodies to HMB45 (gp100),
MART-1, and MITF were also tested, but these failed to consis-
tently stain melanocytes in fixedmouse skin sections and did not
consistently stain mouse B16 melanoma cells fixed according to
the same protocol (data not shown). The vast majority of
neoplastic cells were highly atypical, lacked pigmentation, and
were poorly differentiated, which may also have contributed to
the difficulty encountered in the immunohistochemical analysis.
To circumvent the lack of adequate reagents for immunohisto-
chemical analysis, we used alternative approaches to examine
the lesions for expression of melanocytic lineage genes and
melanoma markers. First, we showed that all tumors displayed
evidence of LSL-BrafV600E locus recombination (Figure 5C).
Then, we used RT-PCR to show evidence of tyrosinase, Trp2,
Pax3, and Silver (the mouse equivalent of gp100) expression
(Figure 5D) in the amelanotic/oligomelanotic malignant lesions.
We hypothesized that the neoplastic cells in the amelanotic/
oligomelanotic malignant lesions were either undifferentiated
or poorly differentiated and of melanocytic origin. To test this,
we generated clonal cell lines from the primary tumors and
treated them with cholera toxin, a known inducer of melanocyte
differentiation (O’Keefe and Cuatrecasas, 1974). Notably, the
clonal lines constitutively expressed the melanocytic markers
tyrosinase, Trp2, and Silver, but the levels of expression of these
genes were markedly increased when cells were treated with
cholera toxin (Figure S3A). Furthermore, cholera toxin induced
the tumor cells to adopt a more differentiated, dendritic
morphology (Figure S3B). Together with the histological, immu-
nohistochemical, and RT-PCR results, these findings provide
strong circumstantial evidence suggesting that the lesions we
observed are oligomelanotic malignant melanomas.
We did not observe any examples of metastatic tumor growth,
although 38% of lesions were ulcerated (Figures 4B and 4C;
Figures S2C and S2D) and neoplastic cells displayed overt
destructive growth destroying subjacent subcutaneous tissues,
skeletal muscle, and, when the lesions affected the ears, the
auricular cartilage (Figures S2A and S2B). In human pathology,
these are diagnostic features used to differentiate malignant
presence of proliferating cells in deep areas. Inset: Ki-67-positive neoplastic
cells. Note the residual skeletal muscle fiber. Scale bars = 200 mm in main
figure; 50 mm in inset.
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Malignant Tumors that Have Features of Melanocytic
Differentiation
(A and B) Low- and high-power micrographs of a spindle cell
lesion expressing S100 protein in the nuclei of the vast
majority of neoplastic cells. Immunohistochemistry was
performed with polyclonal anti-S100 protein antibody
(avidin-biotin-peroxidase/DAB). Scale bars = 200 mm.
(C) PCR-mediated genotyping of the Braf alleles in DNA
extracted from tumors (T) or from the skin of untreated
control (C) mice. The positions of wild-type Braf (WT-Braf),
the LSL-BrafV600E allele, and the Cre recombinase-rearranged
LSL-BrafV600E locus (Lox-BrafV600E) are indicated.
(D) Expression of the melanoma markers tyrosinase, Trp2,
Pax3, and Silver (Si) in tumors (tum) of TM-treated BrafV600E
mice. RNA from melanocyte-rich ear skin (skin) from a wild-
type mouse was used as a positive control. DNA from the
kidneys (kid) was used as a negative control. Numbers refer
to individual mice.from benign melanocytic lesions. Therefore, to test whether
neoplastic cells from these lesions have metastatic potential,
tumor cells were harvested for in vitro culture, engineered to
express firefly luciferase, and injected into the tail veins of
nude mice. Using intravital imaging, the cells were shown to
colonize the lungs in all (15 of 15) of the recipient mice
(Figure 6A). Postmortem examination revealed that the lungs
contained multiple tumor foci and were significantly heavier
than lungs from PBS-injected controls (Figures 6B and 6C).
The metastatic deposits contained neoplastic cells whose
morphology resembled that of cells in the primary tumors
(Figure 6D).
Previous studies have shown that NrasQ61K induces meta-
static melanoma in p16INK4a null mice (Ackermann et al., 2005),
so we examined whether BrafV600E could also stimulate meta-
static melanomas in p16INK4a null animals by crossing the
BrafV600E/CreERT2 mice onto a p16INK4a null background (note
that these mice still express p19Arf [Krimpenfort et al., 2001]).
In the wild-type p16INK4a background, BrafV600E induced mela-
noma in 54% of the mice within 12 months, increasing to 64%
after 14 months and a median latency of 12 months (Figure 6E).
Tumors did not develop in vehicle-treated BrafV600E/CreERT2
mice or in TM-treated controls (Figure 6E; Table 2). However,
in the p16INK4a null background, 80% of the mice developed
tumors within 12 months, and the latency dropped to 7 months
(Figure 6E). In addition, while wild-type p16INK4a animals tended
to develop only single tumors, the p16INK4a null mice generally
developed multiple tumors (data not shown). Surprisingly, the
p16INK4a null mice still developed nevi (Figure 6F), and the nevi
and tumors of wild-type p16INK4a mice still expressed p16INK4a
mRNA (Figure 6G). We sequenced the p16INK4a mRNA from
the tumors and did not detect any mutations within its open
reading frame (data not shown). Commensurate with this, we
demonstrated that p16INK4a protein was expressed in the nuclei
of melanomas from wild-type p16INK4a animals (Figure 6H), sug-
gesting that the protein is active. As a control for the p16INK4astaining, we demonstrated that there was no specific staining
for this protein in tumors from p16INK4a null mice (Figure 6H).
DISCUSSION
In this study, we show that BrafV600E expression induces several
types of melanocytic lesions in mice, including skin hyperpig-
mentation, benign classic and epithelioid blue nevi, and mela-
noma. Nevi and melanoma are genetically linked because
individuals from melanoma-susceptible families have unusually
high numbers of nevi (Hayward, 2000), but the relationship
between BRAF, nevi, and melanoma is unclear because BRAF
mutations are as common in nevi as they are in melanoma
(Pollock et al., 2003). Furthermore, whereas BRAFV600E stimu-
lates melanoma cell proliferation, it induces senescence in mela-
nocytes (Garnett and Marais, 2004; Gray-Schopfer et al., 2006;
Michaloglou et al., 2005; Pollock et al., 2003). Overexpressed
HrasG12V can induce nevi in mice, but the animals do not develop
melanoma unless tumor suppressor genes such as p16INK4a or
p19Arf are also deleted (Ackermann et al., 2005; Chin et al.,
1997, 1999; Huijbers et al., 2006; Powell et al., 1995) or the
animals are treated with carcinogens such as DMBA or ultravi-
olet radiation (Broome Powell et al., 1999; Kannan et al., 2003).
Additionally, although NrasQ61K induces melanoma in p16INK4a
null mice, it does not induce nevi (Ackermann et al., 2005).
Thus, unlike oncogenic Ras, BrafV600E can induce both mela-
nocyte senescence and melanoma in mice, and it does so
without the need for additional manipulation of the genome.
Furthermore, BrafV600E was expressed off the endogenous Braf
gene and balanced over a wild-type allele, and it therefore
closely mimics the genetics of the human disease. We have
previously shown that BRAFV600E transforms immortalized mela-
nocytes (Wellbrock et al., 2004), but these results are important
because they establish that BrafV600E can be a founder event in
melanomagenesis and are consistent with a model whereby
BrafV600E stimulates melanocytic proliferation but cannot induceCancer Cell 15, 294–303, April 7, 2009 ª2009 Elsevier Inc. 299
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3igure 6. Metastatic Potential and p16 Status of BrafV600E Tumors
A) Intravital imaging of mice injected with 3 3 105 luciferase-expressing
rafV600E-induced melanoma cells (left) or with PBS (right) in the tail vein.
he image was captured 31 days postinjection.
B) Lungs from mice injected with 3 3 105 luciferase-expressing BrafV600E-
duced melanoma cells (left) or with PBS (right) in the tail vein. Tumor nodules
re indicated by arrowheads.
C) Box plot of lung weights frommice injected with PBS or 33 105 luciferase-
xpressing BrafV600E-induced melanoma cells (Cells) in the tail vein. Results
re for 15 mice in each group; lungs were removed 27–32 days postinjection.
ower quartile, median, and upper quartile are shown, with whiskers extending
o the lowest and highest values.
D) Photomicrograph of metastatic melanoma deposit in the lung of a recipient
ouse. Scale bar = 500 mm.
E) Kaplan-Meier plots showing disease-free progression of study mice.
he TM-treated Braf+/V600E;Tyr::CreERT2+/o;p16+/+ (V/E;Cre;p16 WT) group
ontained 28 animals, the TM-treated Braf+/V600E;Tyr::CreERT2+/o;p16/
V/E;Cre;p16 null) group contained 10 animals, and controls included 800 Cancer Cell 15, 294–303, April 7, 2009 ª2009 Elsevier Inc.full transformation, so the cells become senescent and form
a nevus. Eventually, some cells escape this senescence and
progress to form a tumor, presumably through acquisition of
additional mutations or genetic events. Although blue nevi
were common at the periphery of the melanomas in our mice
(Figures 4B and 4C) and nevus remnants in contiguity with
melanomas have been described in 26%–85% of human nevi
(Bevona et al., 2003; Greene et al., 1985), it is not possible to
formally prove whether the tumors in our mice emerged directly
out of nevi or whether they developed de novo.
Our data also suggest that BrafV600E is more efficient at
inducing melanoma than oncogenic Ras. With BrafV600E, 11%
of mice (3 of 28) developed melanoma within 6 months, rising
to 54% within a year and 64% within 14 months. HrasG12V
induced melanoma in 3% of mice (1 of 41) in 6 months in one
study (Chin et al., 1997) but did not induce melanoma at all in
up to 8 months in another (Huijbers et al., 2006). NrasQ61K
induced melanoma in 28% of mice (4 of 14) within a year (Acker-
mann et al., 2005). These data reflect clinical experience in
humans, where BRAF mutations are three times more common
than RAS mutations (Garnett and Marais, 2004). However, the
apparent increased potency of BrafV600E may reflect differences
in transgene design and oncogene expression levels rather than
true biological differences between BrafV600E and oncogenic
Ras. This will need to be fully tested as more physiological
models of melanoma using oncogenic Ras are developed.
The BrafV600E-induced lesions we observed present an inter-
esting paradox because blue nevi are comparatively rare in
humans and do not generally harbor BRAF mutations (Yazdi
et al., 2003). The predominance of dermal lesions in the BrafV600E
mice compared to humans may occur because melanocytes are
predominantly dermal and rarely epidermal in mice, whereas the
inverse is true in human skin (Hirobe, 1992). Nevertheless, the
BrafV600E tumors in our mice bear many characteristics of human
oligomelanotic melanoma, including classic histological features
such as nuclear pseudoinclusions and, although rare, pigmented
neoplastic cells. We did not observe any evidence of metastasis
in ourmice. However, given the presence of ulceration, asymme-
try, overt destructive growth patterns, and atypical cells with
conspicuous nuclear pleomorphism (Figure 5A), histological
features that are predictive of malignant behavior andmetastatic
potential in human melanoma, the BrafV600E-induced tumors are
likely to have metastatic potential. In support of this hypothesis,
we have demonstrated that the tumor cells from these lesions
can colonize the lungs of recipient mice when injected via the
tail vein (Figures 5B–5E). Taken together, these data provide
strong evidence of the metastatic potential of these oligomela-
notic melanomas.
Braf+/V600E;Tyr::CreERT2+/o;p16/ (V/E;Cre;p16 null) vehicle-treated or
untreated animals. Additional controls are described in Table 2.
(F) Photograph showing nevi on the back of a TM-treated Braf+/V600E;
Tyr::CreERT2+/o;p16INK4a/ mouse. The fur has been removed to reveal the
lesions.
(G) p16INK4a (p16) and Gapdh expression in skin harboring nevi or in tumors or
liver from BrafV600E-expressing mice. Skin from a wild-type mouse (WT skin)
served as a negative control.
(H) p16INK4a protein expression in BrafV600E-induced tumors in p16INK4a+/+ (left)
and p16INK4a/ (right) mice. Sections were counterstained with hematoxylin.
Scale bar = 50 mm.
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Genotype Phenotype Treatment Disease-free after 12 Months
Braf+/LSL-V600E;Tyr::CreERT2+/o;p16INK4a+/+ BrafV600E/CreERT2/p16WT untreated 8/8
Braf+/+;Tyr::CreERT2+/o;p16+/+ BrafWT/CreERT2/p16WT treated 14/14
Braf+/LSL-V600E;Tyr::CreERT2o/o;p16+/+ BrafV600E/p16WT treated 6/6
Braf+/+;Tyr::CreERT2o/o;p16+/+ BrafWT/p16WT treated 5/5
Braf+/LSL-V600E;Tyr::CreERT2+/o;p16/ BrafV600E/CreERT2/p16null untreated 8/8
Braf+/+;Tyr::CreERT2+/o;p16/ BrafWT/CreERT2/p16null treated 5/5
Braf+/LSL-V600E;Tyr::CreERT2o/o;p16/ BrafV600E/p16null treated 4/4
Untreated controls were either untreated or treated with vehicle (ethanol) only. Treated controls were treated with tamoxifen as described for exper-
imental groups.We investigated the role of p16INK4a in theseBrafV600E-induced
tumors because metastatic lesions are seen in NrasQ61K-
induced melanomas in p16INK4a null mice (Ackermann et al.,
2005). Loss of p16INK4a did not augment metastatic behavior in
the BrafV600E-induced melanomas. However, we did find that
although p16INK4a was upregulated in BrafV600E-induced nevi
(Figure 5H), p16INK4a null mice still developed nevi (Figure 5G).
We also found that nuclear p16INK4a was expressed in
BrafV600E-induced melanomas (Figure 5I). These observations
appear counterintuitive since increased expression of p16INK4a
is a marker of senescence that is thought to provide protection
from melanoma progression, and its loss is perceived to be an
important step in melanomagenesis (Bennett, 2003). However,
our findings are consistent with the clinical observations in hu-
mans. First, patients who carry mutations in both CDKN2A
alleles and fail to express functional p16INK4a still develop nevi
(Pavel et al., 2003). Second, although p16INK4a is lost in most
melanoma cell lines (Kamb et al., 1994), it is less commonly
lost in clinical samples of melanoma. Thus, although early
studies reported p16INK4amutations in 85%of familial melanoma
cases (Gruis et al., 1995), larger population-based studies have
reported mutation rates of 8%–40% (Goldstein et al., 2007;
Holland et al., 1999; Ruiz et al., 1999). Furthermore, in sporadic
melanoma, fewer than 2% of cases have mutations that affect
p16INK4a (Aitken et al., 1999; Orlow et al., 2007). Nuclear
p16INK4a staining is still seen in 30%–85%of primary melanomas
(Sanki et al., 2007; Sirigu et al., 2006), persists in microinvasive
disease (Tuthill and Reed, 2007), and is reported in 15%of meta-
static melanoma lesions (Sanki et al., 2007).
Thus, in accord with human physiology, although p16INK4a is
upregulated in senescent mouse melanocytes, it is not required
for the senescence response. Consequently, although p16INK4a
is a tumor suppressor and a marker of senescence, it is not
essential for nevus formation, and in agreement with human
studies (Michaloglou et al., 2005), we conclude that BrafV600E-
mediated oncogene-induced senescence is independent of
p16INK4a. This suggests that other genes must contribute to, or
be responsible for mediating, this response in melanocytes.
Also in accord with human physiology, we have shown that
p16INK4a loss is not essential formelanoma progression, although
it does appear to regulate disease latency and penetrance.
In summary, we have developed a mouse model of melanoma
driven by oncogenic Braf. The tumors we observed mimic those
of amelanotic/oligomelanotic malignant metastatic melanoma in
humans and are driven by a single human-relevant oncogeneexpressed at physiological levels. We have established that
oncogenic Braf can induce melanocyte senescence in vivo and
thatBrafmutations can be founder genetic lesions in melanoma-
genesis. The long latency required for the development of mela-
noma demonstrates that oncogenic Braf alone is not sufficient to
induce melanoma and that additional genetic lesions are
required. The model we present here will play an important role
in identifying those lesions.
EXPERIMENTAL PROCEDURES
Experimental Animals and Genotyping
Animal experiments were carried out under Home Office license authority in
accordance with United Kingdom Coordinating Committee on Cancer
Research guidelines (Workman et al., 1988) and with approval of the local
Ethics Committee. Generation and genotyping of transgenic animals has
been described previously (Mercer et al., 2005; Yajima et al., 2006). Tamoxifen
(Sigma T5648) was freshly prepared in 100% ethanol. For tail vein injections,
tumor cell lines were established by collecting tumors in sterile PBS, transfer-
ring them to DMEM/10%FCS and Primocin (0.1mg/ml; InvivoGen), and disso-
ciating them mechanically. Cells were allowed to attach to standard tissue
culture plastic for 7 days, and clonal lines were derived by limiting dilution.
Where appropriate, cells were treated with 300 pM cholera toxin (dissolved
in PBS) or left untreated for 48 hr. For intravital imaging, cells were engineered
to express firefly luciferase by transfection with the vector pMCEF-luciferase
for clonal selection in G481 (4 mg/ml in DMEM/10% FCS). Tumor cells
expressing luciferase (3 3 105 cells in 100 ml PBS) were injected into the tail
vein of nude (NCr-nu) mice. Control mice received PBS. For intravital imaging,
mice received intraperitoneal injections of D-luciferin in water (150mg/kg body
weight) 10 min before imaging. The animals were anesthetized with isoflurane,
and tumors were imaged in an IVIS 100 (Xenogen), collecting data for 1 min for
analysis with Living Image software.
Histology and Immunohistochemistry
Tumors were fixed in 10% buffered formalin and embedded in paraffin.
Immunohistochemistry was performed on 3–10 mm sections stained with
hematoxylin and eosin using standard protocols. p16INK4a antigen was
retrieved by microwave (18 min in citrate buffer) and detection with rabbit
polyclonal antibody (p16INK4a; Santa Cruz, 1:50) and a Vectastain Elite ABC
kit (Vector Laboratories) according to the manufacturer’s instructions. For
S100 and Ki-67 staining, antigen retrieval was performed in citrate buffer (pH
6.0, 30 min). S100 staining was revealed using a rabbit polyclonal antibody
(Dako, 1:1000), a Rabbit enVision Peroxidase kit, and the AEC substrate chro-
mogen (Dako). Ki-67 staining was revealed using a rat monoclonal antibody
(Dako, 1:25), a rat Vectastain ABC kit (Vector Laboratories), and DAB as chro-
mogen. Sections were counterstained with Harris’s hematoxylin. Samples
were stained for senescence-associated b-galactosidase as described previ-
ously (Gray-Schopfer et al., 2006). For bleaching prior to staining, sections
were incubated in 0.1%KMnO4 (20min) followed by 0.5% oxalic acid (12min).Cancer Cell 15, 294–303, April 7, 2009 ª2009 Elsevier Inc. 301
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DNA and RNA were extracted from snap-frozen tissues or cells using DNeasy
and RNeasy kits, respectively (QIAGEN). First-strand cDNA synthesis from
RNA was performed with 500 ng of total RNA and random hexanucleotides.
For RT-PCR, specific genes were amplified under conditions in which
amplification was still linear. Primer sequences are listed in the Supplemental
Experimental Procedures.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
three figures and can be found with this article online at http://www.
cancercell.org/supplemental/S1535-6108(09)00074-9.
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